Trial reportVaccine2017
CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination.
Trial report in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 64 citations in OpenAlex.
- Neutrophils induce effective antibody responses to the pneumococcal conjugate vaccine by inhibiting T regulatory cells.Journal of leukocyte biology · 2026Article
- The Impact of Zinc on T Cell Motility and the Immunological Synapse.International journal of molecular sciences · 2026Article
- Brain-infiltrating CD8 T cells retain functional activity to protect against acute Zika virus infection.Scientific reports · 2026Article
- Maternal probiotic exposure enhances CD8 T cell protective neonatal immunity and modulates offspring metabolome to control influenza virus infection.Gut microbes · 2025Article
- Tick-borne coinfections modulate CD8Infection and immunity · 2025Article
- Chimeric PRR T-cell-engager targeting cell surface β-1,3-glucan for invasive candidiasis.PLoS pathogens · 2025Article
- Molecular and Immunological Properties of a Chimeric Glycosyl Hydrolase 18 Based on Immunoinformatics Approaches: A Design of a New Anti-ACS pharmacology & translational science · 2025Article
- Sex-based difference in immune responses and efficacy of the pneumococcal conjugate vaccine.Journal of leukocyte biology · 2024Article
- Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection.NPJ vaccines · 2024Article
- Within-host bayesian joint modeling of longitudinal and time-to-event data of Leishmania infection.PloS one · 2024Article
- Late-rising CD4 T cells resolve mouse cytomegalovirus persistent replication in the salivary gland.PLoS pathogens · 2024Article
- CD28/PD1 co-expression: dual impact on CD8Journal of experimental & clinical cancer research : CR · 2023Article
- Article
- Loss of CD4Immunity · 2023Article
- TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.Journal for immunotherapy of cancer · 2023Article
- Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.Journal for immunotherapy of cancer · 2023Article
- A viral-specific CD4Frontiers in immunology · 2023Article
- CD4 expression in effector T cells depends on DNA demethylation over a developmentally established stimulus-responsive element.Nature communications · 2022Article
- Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.Frontiers in immunology · 2022Article
- Activated B lymphocytes and tumor cell lysate as an effective cellular cancer vaccine.Cancer immunology, immunotherapy : CII · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundDetermining the efficacy of human vaccines that induce antigen-specific protective CD4 T cell responses against pathogens can be particularly challenging to evaluate. Surface expression of CD11a and CD49d has been shown to identify antigen-specific CD4 T cells against viral pathogens in mice. We hypothesized that CD11a and CD49d would also serve as markers of human antigen-specific T cells responding to vaccination.
methodsA phase I vaccine trial enabled us to evaluate a novel gating strategy based on surface expression of CD11a and CD49d as a means of detecting antigen-specific, cytokine producing CD4 and CD8 T cells induced after vaccination of naïve individuals against leishmaniasis. Three study groups received LEISH-F3 recombinant protein combined with either squalene oil-in-water emulsion (SE) alone, SE with the synthetic TLR-4 ligand glucopyranosyl lipid adjuvant (GLA-SE), or SE with Salmonella minnesota-derived monophosphoryl lipid A (MPL-SE). Individuals were given 3 vaccine doses, on days 0, 28 and 168.
resultsStarting after the first vaccine dose, the frequency of both CD11a
conclusionsOur results suggest that the change in the frequency of CD11a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.